Fundamental Analysis of Protagonist Therapeutics Inc - Growth / Value Index
PTGX - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 12.50
Price to Book Ratio of 2609.16 suggesting that it is very expensive
Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 5039.25 | -11374.21 | -104858.61 % | |
Price to Book | 2389.32 | 4746.07 | 74022.63 % | 3.19 |
Price to Sales | 2593.76 | 26631.57 | 51176.63 % | |
Enterprise Value to EBITDA Multiple | 9.53 | -11648.16 | -115308.83 % |
PTGX - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Good Score of 73.12
During the past twelve months, the company has given a strong Return On Equity of 47.41%
During the past twelve months, the company has given a strong Return On Asset of 43.17%
During the past twelve months, the company has given a strong Net Margin of 51.47%
All key Trailing Twelve Months Margin growing by 15 %
Piotroski F Score - Stable Value of 4.0
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
Steady Growth in EPS for last four quarters
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 47.41 | -41.73 | 29.38 % | 37.00 |
Return On Asset | 43.17 | -39.25 | 23.62 % | 32.95 |
Net Profit Margin | 51.47 | -234.14 | 51.15 % | 81.32 |
Operating Profit Margin | 47.21 | -255.36 | 48.33 % | 80.92 |
EBITDA Margin | 48.83 | -228.61 | 51.22 % | 80.92 |
Highlights
Market Cap | 1651.06 M |
Enterprise Value | 1465.47 M |
Price/Book TTM | 2389.32 |
Outstanding Share | 58652.10 K |
Float/ Outstanding Share | 73.37% |
Dividend Yield | 0 % |
Share Holding
Guru Numbers
Price/Graham No | 1031.00 |
Peter Lynch Ratio | 0 |
Piotroski F Score | 4.00 |
Altman Z Score | 44.15 |
Sloan Ratio | -0.060 |
Peter Lynch Fair Value | 0 |
PTGX - Growth Highlights
Growth Analysis
STRONG JUMP IN NET SALE : YoY growth
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Poor Score of 25.38
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 314953 K | 125.73 % | 324.92 % |
Gross Profit | 313305 K | 125.73 % | 324.92 % |
EBITDA | 153796 K | 10.11 % | 632.45 % |
Net Profit | 162110 K | 10.28 % | 658.51 % |
EPS | 0.0056 | 99.90 % | NA |
PTGX - Stability Highlights
Stability Analysis
Altman Z Score of 48.43 suggests good Stability
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
Cash ratio of 16.06
Company financial liquidity has improved
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0.0034 | -70.95 % | 0.0008 |
Cash Ratio | 16.06 | 110.94 % | |
Quick Ratio | 17.20 | 120.53 % | 15.72 |
Shareholders Equity | 94.06 | 8.16 % | |
Debt to EBITDA | -0.0083 | 58.80 % |
Historical Valuation Ratios of Protagonist Therapeutics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Protagonist Therapeutics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Protagonist Therapeutics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Protagonist Therapeutics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)